Lazier, sent email to IR. Curious if they plan on issuing PR to announce they have submitted the safety analysis along with DSMB’s recommendation to halt the remaining trial.
That would make a nice teaser going into earnings next week. More importantly, it starts the 60 day window for the FDA to respond.